T Lymphocytes and Their Potential Role in Dementia with Lewy Bodies.

Jay Amin, Claire Gee, Kiran Stowell, Daisy Coulthard, Delphine Boche
Author Information
  1. Jay Amin: Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK. ORCID
  2. Claire Gee: Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK.
  3. Kiran Stowell: Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK.
  4. Daisy Coulthard: Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK.
  5. Delphine Boche: Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK. ORCID

Abstract

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative cause of dementia. People with DLB have an inferior prognosis compared to Alzheimer's disease (AD), but the diseases overlap in their neuropathology and clinical syndrome. It is imperative that we enhance our understanding of the aetiology and pathogenesis of DLB. The impact of peripheral inflammation on the brain in dementia has been increasingly explored in recent years, with T lymphocyte recruitment into brain parenchyma identified in AD and Parkinson's disease. There is now a growing range of literature emerging on the potential role of innate and adaptive immune cells in DLB, including T lymphocytes. In this review, we examine the profile of T lymphocytes in DLB, focusing on studies of post-mortem brain tissue, cerebrospinal fluid, and the blood compartment. We present an integrated viewpoint on the results of these studies by proposing how changes to the T lymphocyte profile in the brain and periphery may relate to each other. Improving our understanding of T lymphocytes in DLB has the potential to guide the development of disease-modifying treatments.

Keywords

References

  1. Front Neurol. 2018 Dec 18;9:1081 [PMID: 30619041]
  2. Front Mol Neurosci. 2022 Oct 24;15:1013933 [PMID: 36353359]
  3. Brain. 2000 Jun;123 ( Pt 6):1092-101 [PMID: 10825349]
  4. J Neural Transm (Vienna). 2018 Apr;125(4):615-650 [PMID: 29222591]
  5. Vasc Biol. 2020 Mar 20;2(1):H1-H18 [PMID: 32923970]
  6. Nature. 2017 Jun 29;546(7660):656-661 [PMID: 28636593]
  7. Eur J Immunol. 2010 Jul;40(7):1830-5 [PMID: 20583029]
  8. Front Cell Neurosci. 2012 Sep 19;6:38 [PMID: 23049498]
  9. Neurology. 2017 Jul 4;89(1):88-100 [PMID: 28592453]
  10. J Exp Med. 2011 Feb 14;208(2):327-39 [PMID: 21300915]
  11. Neuron. 2022 Nov 2;110(21):3566-3581 [PMID: 36327898]
  12. Nature. 2023 Mar;615(7953):668-677 [PMID: 36890231]
  13. PLoS One. 2014 Feb 25;9(2):e89327 [PMID: 24586691]
  14. Neurology. 2000 Jul 12;55(1):132-4 [PMID: 10891923]
  15. Nat Rev Immunol. 2019 Sep;19(9):573-583 [PMID: 31186548]
  16. Cold Spring Harb Perspect Med. 2012 Aug 01;2(8): [PMID: 22908195]
  17. Biomed Res Int. 2015;2015:521957 [PMID: 26583116]
  18. J Neuroinflammation. 2016 Jun 02;13(1):135 [PMID: 27256292]
  19. J Neurosci. 2013 Jun 5;33(23):9592-600 [PMID: 23739956]
  20. Int J Biochem Cell Biol. 1998 Oct;30(10):1075-9 [PMID: 9785472]
  21. J Neurol Sci. 2010 Feb 15;289(1-2):18-22 [PMID: 19733364]
  22. Nat Commun. 2018 Nov 2;9(1):4593 [PMID: 30389931]
  23. J Neurosci Res. 1991 Feb;28(2):254-60 [PMID: 2033653]
  24. Cell Res. 2012 Jan;22(1):33-42 [PMID: 22212481]
  25. J Exp Med. 2007 Sep 3;204(9):2023-30 [PMID: 17682068]
  26. Mol Neurobiol. 2017 Dec;54(10):7762-7776 [PMID: 27844285]
  27. Elife. 2022 Jul 01;11: [PMID: 35775627]
  28. Int J Mol Sci. 2017 Aug 10;18(8): [PMID: 28796199]
  29. Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8284-E8293 [PMID: 28900002]
  30. Acta Neuropathol Commun. 2020 Dec 3;8(1):211 [PMID: 33272323]
  31. Brain Pathol. 2015 Jul;25(4):401-8 [PMID: 25103200]
  32. Lancet Neurol. 2015 Apr;14(4):388-405 [PMID: 25792098]
  33. J Clin Invest. 2009 Jan;119(1):182-92 [PMID: 19104149]
  34. Sci Rep. 2021 Jan 11;11(1):302 [PMID: 33432042]
  35. Immunol Rev. 2023 Jul;316(1):160-175 [PMID: 37098109]
  36. Science. 2021 Nov 12;374(6569):868-874 [PMID: 34648304]
  37. Neurodegener Dis. 2018;18(1):49-56 [PMID: 29402847]
  38. Front Aging Neurosci. 2022 May 06;14:888946 [PMID: 35601620]
  39. Curr Neurol Neurosci Rep. 2015 Apr;15(4):17 [PMID: 25716012]
  40. Front Immunol. 2018 Jan 25;8:1905 [PMID: 29422891]
  41. Alzheimers Dement (Amst). 2017 Dec 27;10:143-152 [PMID: 29780862]
  42. Eur J Immunol. 2000 Apr;30(4):1002-9 [PMID: 10760787]
  43. Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):49 [PMID: 30263032]
  44. Neurology. 2005 Dec 27;65(12):1863-72 [PMID: 16237129]
  45. J Immunol. 2006 Dec 1;177(11):8053-64 [PMID: 17114479]
  46. Transl Neurodegener. 2016 Apr 05;5:7 [PMID: 27054030]
  47. J Leukoc Biol. 2003 May;73(5):584-90 [PMID: 12714572]
  48. Eur J Immunol. 2013 Nov;43(11):2797-809 [PMID: 24258910]
  49. Front Pharmacol. 2018 May 04;9:417 [PMID: 29780321]
  50. J Neuroinflammation. 2020 Jul 17;17(1):214 [PMID: 32680537]
  51. Front Immunol. 2023 Apr 04;14:1154699 [PMID: 37081887]
  52. J Neuroinflammation. 2012 Jul 02;9:155 [PMID: 22747919]
  53. J Neuroimmunol. 2002 Mar;124(1-2):83-92 [PMID: 11958825]
  54. Nature. 2020 Jan;577(7790):399-404 [PMID: 31915375]
  55. Neurobiol Dis. 2022 Jun 15;168:105698 [PMID: 35314318]
  56. Am J Geriatr Psychiatry. 2020 Jan;28(1):75-86 [PMID: 31327631]
  57. Arch Immunol Ther Exp (Warsz). 2014 Dec;62(6):449-58 [PMID: 24879097]
  58. Nat Commun. 2020 Apr 20;11(1):1875 [PMID: 32313102]
  59. Brain Behav Immun. 2020 Oct;89:67-86 [PMID: 32479993]
  60. J Comp Neurol. 2016 Apr 15;524(6):1236-58 [PMID: 26358191]
  61. Lancet Neurol. 2017 May;16(5):390-398 [PMID: 28342649]
  62. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1219-1226 [PMID: 32968032]
  63. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):112-9 [PMID: 15312274]
  64. J Neuroimmunol. 2003 Feb;135(1-2):154-60 [PMID: 12576236]
  65. Transl Psychiatry. 2020 Aug 3;10(1):267 [PMID: 32747635]
  66. Semin Immunopathol. 2022 Nov;44(6):855-867 [PMID: 35364699]
  67. Acta Neuropathol. 2005 Feb;109(2):141-50 [PMID: 15619128]
  68. J Neural Transm (Vienna). 2011 Jan;118(1):23-6 [PMID: 20972807]
  69. Neuropathol Appl Neurobiol. 2013 Feb;39(1):3-18 [PMID: 23252647]
  70. Mov Disord. 2018 Jul;33(6):982-991 [PMID: 29570843]
  71. Front Immunol. 2019 Sep 12;10:2171 [PMID: 31572381]

Grants

  1. Research Management Committee grant/University of Southampton

Word Cloud

Created with Highcharts 10.0.0TDLBbrainlymphocytesLewydementiaDementiabodiesdiseaseADunderstandinginflammationlymphocytepotentialadaptivecellsprofilestudiessecondcommonneurodegenerativecausePeopleinferiorprognosiscomparedAlzheimer'sdiseasesoverlapneuropathologyclinicalsyndromeimperativeenhanceaetiologypathogenesisimpactperipheralincreasinglyexploredrecentyearsrecruitmentparenchymaidentifiedParkinson'snowgrowingrangeliteratureemergingroleinnateimmuneincludingreviewexaminefocusingpost-mortemtissuecerebrospinalfluidbloodcompartmentpresentintegratedviewpointresultsproposingchangesperipherymayrelateImprovingguidedevelopmentdisease-modifyingtreatmentsLymphocytesPotentialRoleBodiesimmunity

Similar Articles

Cited By